• CD28 targeting
  • How it works

Keystone Symposia – Next Generation Antibody Therapeutics: From Discovery to Patient

Sara Majocchi

CD28 bispecific antibodies to be presented at PEGS Europe

14th annual PEGS Europe - Sara Majocchi -

SITC 2022, NI-2901 bispecific antibody poster presentation

37th Annual Meeting & Pre-Conference Programs (SITC)

First-in-human trial of NI-1801 in patients with solid cancers expressing mesothelin (MSLN)

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B‑cell lymphoma xenograft model. Xavier Chauchet, Laura Cons, et al.

Xavier Chauchet, Laura Cons, et al.

TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

New publication in Molecular Therapy

Written by Remi Jeandenand on . Posted in News

Read more

LinkedIn